7.3K
MPRare Biotech Catalyst: FDA Decision on Ultra-Rare Pediatric Disease Treatment. We talk about a rare, date-stamped asymmetric setup in the biotech space. On September 30th, the FDA will decide on the first-ever treatment for a fatal, ultra-rare pediatric disease. This small-cap company has Priority Review, full rights to a potential Priority Review Voucher, and a commercialization partner lined up for up to 129 million dollar stream for milestones and royalties. The current price is around $3.5, and this is a true binary event with a base case of 30-60% gains and a bull case of 80-120% if approval plus monetization news stack. The decision is expected after hours on September 30th. #biotech #FDA #pediatricdisease #smallcap #priorityreview #commercialization #binaryevent #catalyst #asymmetricmath
@mparkerthesis
